Myriad Bundle
Who are Myriad Genetics' customers?
Understanding customer demographics and target markets is paramount for Myriad Genetics, a pioneer in molecular diagnostics, as it navigates the complex and evolving landscape of precision medicine. A pivotal moment for the company was the initial discovery of the BRCA1/BRCA2 genes in the mid-1990s and the subsequent launch of its BRACAnalysis test, which fundamentally created the market for hereditary cancer genetic testing and established Myriad's early dominance.
This groundbreaking innovation underscored the critical importance of genetic insights for proactive health management and personalized treatment, leading to a significant shift in how healthcare decisions are made.
What is Customer Demographics and Target Market of Myriad Genetics?
Myriad Genetics, Inc. was established in 1991 in Salt Lake City, Utah, by a visionary team. Their initial vision centered on leveraging genetic information to assess disease risk and guide medical decisions, primarily focusing on hereditary cancers. However, the genetic testing landscape underwent significant transformation, notably after the 2013 U.S. Supreme Court ruling on gene patents, which invalidated key patents and increased competition for tests like BRACAnalysis. This shift necessitated a strategic diversification for Myriad Genetics, evolving from its original singular focus on hereditary cancer to a broader portfolio encompassing oncology, women's health, and pharmacogenomics for mental health. This evolution has reshaped its patient profiles and market position, as detailed in our Myriad PESTEL Analysis.
Who Are Myriad’s Main Customers?
The primary customer segments for the company are healthcare providers who order genetic tests, and the patients who utilize these services. This dual approach involves direct engagement with medical professionals and indirect influence on consumers.
Healthcare Providers as Direct Customers
Key healthcare providers include oncologists, OB/GYNs, psychiatrists, urologists, dermatopathologists, and rheumatologists. Their decisions to order genetic tests directly drive the utilization of the company's services.
Patients as End-Users
Patients are the ultimate beneficiaries, seeking proactive health management, diagnostic clarity, or treatment guidance. Understanding their needs is crucial for the company's market segmentation.
Diverse Patient Demographics
Customer demographics are varied, reflecting the broad range of tests offered in oncology, women's health, and mental health. Key segments include adults pursuing proactive health assessments or diagnostic clarity, and those diagnosed with specific conditions.
Growth Drivers and Strategic Focus
The Pharmacogenomics segment saw a 14% year-over-year increase in 2024. Prenatal testing grew 17% for fiscal year 2024, and hereditary cancer testing volumes increased 10% in Q1 2024.
Addressing Healthcare Disparities and Market Evolution
The company is committed to inclusivity, ensuring tests like MyRisk with RiskScore are applicable across all ancestries. This strategic pivot, initiated after 2013, broadened the company's portfolio beyond its initial hereditary cancer focus, reflecting market shifts and a diversification strategy. This evolution is detailed in the Brief History of Myriad.
- Focus on the Cancer Care Continuum (CCC).
- Emphasis on high-growth segments like Molecular Residual Disease (MRD) detection.
- Anticipated early access launch for the Precise MRD test in the first half of 2026.
- Access to healthcare and insurance coverage are significant factors for test utilization.
Myriad SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Do Myriad’s Customers Want?
The Myriad Company's customer base, encompassing both healthcare providers and patients, is fundamentally driven by the need for precise, actionable, and personalized health insights. They seek clarity on genetic predispositions, optimized treatment efficacy, and the minimization of adverse drug reactions. For patients, a significant psychological driver is the pursuit of reassurance and the reduction of anxiety surrounding health screenings.
Precision and Actionability
Customers require genetic tests that offer high accuracy and deliver results that directly inform critical health decisions and treatment pathways.
Personalized Health Guidance
There is a strong demand for information that helps in understanding genetic predispositions and tailoring treatments for better efficacy and fewer side effects.
Reassurance and Reduced Anxiety
For patients, genetic testing provides a sense of reassurance, particularly when facing health concerns or undergoing screenings. A 2025 survey indicated that 75% of women found genetic testing reassuring.
Informed Clinical Decisions
Healthcare providers, such as oncologists and psychiatrists, rely on accurate tests to personalize cancer treatment plans and guide medication selection for mental health conditions.
Addressing Unmet Needs
The company addresses critical needs in early cancer detection, comprehensive prenatal screening, and personalized medication management for mental health disorders.
Market Adaptation and Innovation
The company's product development is shaped by market trends, with a focus on personalized medicine and preventative care, as seen in upcoming product expansions.
The purchasing behaviors of healthcare providers are significantly influenced by the demand for highly accurate and reliable tests that yield clear, easily interpretable results. These results are crucial for informing critical health decisions and guiding treatment and management strategies. For instance, oncologists specifically seek tests that enable the personalization of cancer treatment plans, while psychiatrists utilize tests to inform the selection of appropriate medications for mental health conditions. The company effectively addresses unmet needs such as the growing demand for early detection and personalized treatment in oncology, comprehensive prenatal screening for fetal chromosomal disorders, and crucial guidance for medication selection in the realm of mental health. This responsiveness to market needs is a key aspect of the Marketing Strategy of Myriad.
Key Customer Preferences and Influences
Customer preferences are shaped by the need for scientific expertise, innovation, and unwavering quality across all product lines, including oncology, women's health, and mental health offerings.
- Demand for early detection and personalized treatment in oncology.
- Need for comprehensive prenatal screening for fetal chromosomal disorders.
- Requirement for guidance in medication selection for mental health conditions.
- Preference for tests that accurately assess disease risk and monitor progression.
Myriad PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Where does Myriad operate?
The company's primary market presence is within the United States, where it holds its strongest market share. There is a strategic focus on increasing revenue from international markets, with active global expansion underway to offer its molecular diagnostics worldwide.
Core Geographic Focus
The United States represents the company's core geographic focus and where its strongest market share is held. This region is central to its operational strategy and revenue generation.
International Expansion Strategy
The company is strategically realigning international operations to concentrate on high-growth market opportunities. This includes key regions such as Germany, France, and Japan.
Growth in Japan Market
Significant growth has been observed in Japan, with BRACAnalysis CDx test volume increasing by 200% year-over-year in Q3 2020. This surge followed regulatory approval for its use in pancreatic and prostate cancer.
European Operations Support
European customers are supported through testing conducted at the company's clinical laboratory at its global headquarters in Salt Lake City. This centralized approach ensures consistent service delivery.
Localization of offerings and partnerships are key to succeeding in diverse international markets. This includes licensing and providing technological support to leading pathology institutes in Germany and France for tests like myChoice CDx. A notable partnership with Burning Rock Biotech in China aimed to provide myChoice for HRD testing in clinical studies, thereby expanding access to proprietary technology in a critical Asian market. In August 2024, the company divested its international EndoPredict business, a strategic move to withdraw from certain non-core international operations and sharpen its focus on primary growth areas. The strategic overhaul unveiled in 2024-2025 prioritizes its Cancer Care Continuum strategy, which, while largely focused on the U.S. market, also encompasses the global expansion of its most impactful tests. This aligns with the company's broader Mission, Vision & Core Values of Myriad.
German and French Market Engagement
The company localizes its offerings by providing technological support to pathology institutes in Germany and France. This includes support for tests such as myChoice CDx.
Partnership in China
A partnership with Burning Rock Biotech in China was established to provide myChoice for HRD testing in clinical studies. This expanded access to proprietary technology in a key Asian market.
Divestment of EndoPredict Business
In August 2024, the company divested its international EndoPredict business. This action signaled a strategic withdrawal from specific non-core international operations.
2024-2025 Strategic Overhaul
The strategic overhaul prioritizes the Cancer Care Continuum strategy. This strategy largely focuses on the U.S. market but also includes global expansion of impactful tests.
Myriad Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
How Does Myriad Win & Keep Customers?
The company employs a dual strategy for customer acquisition and retention, focusing on building strong relationships with healthcare providers while also engaging directly with patients. This approach aims to ensure broad market penetration and sustained customer loyalty.
Customer Acquisition: Healthcare Provider Focus
A significant part of customer acquisition relies on a dedicated sales force of approximately 500 individuals in the U.S. as of February 2025. These professionals cultivate relationships with specialists such as oncologists, OB/GYNs, and psychiatrists, providing essential information and support for the company's diagnostic tests.
Customer Acquisition: Digital and Direct Engagement
Digital marketing channels, including social media, SEM, and email campaigns, are used to reach both healthcare professionals and patients. Content marketing, featuring educational resources and patient stories, further supports patient awareness and encourages physician-ordered testing.
Strategic Partnerships and Direct-to-Consumer Expansion
Strategic collaborations, such as the February 2025 integration with PATHOMIQ for AI in oncology, and the Q4 2024 partnership with jscreen, broaden market reach. The acquisition of Gateway Genomics in November 2022 expanded direct-to-consumer offerings, enabling earlier engagement with women during pregnancy.
Customer Retention: Operational Excellence and Innovation
Retention is driven by operational efficiency, with 88% of samples processed within industry-leading turnaround times. Continuous innovation, including pipeline developments like the expanded gene panel for the MyRisk Hereditary Cancer Test in 2025 and the Precise MRD launch in early 2026, enhances existing offerings and introduces new value.
The company leverages advanced analytics and marketing automation to personalize customer experiences and optimize strategies. Patient and provider portals streamline access to results and order management, contributing to overall customer satisfaction and reinforcing loyalty. This integrated approach, combining traditional outreach with digital engagement and strategic alliances, is key to strengthening customer lifetime value, aligning with the Growth Strategy of Myriad.
Sales Force Engagement
Approximately 500 sales representatives in the U.S. as of February 2025 actively engage with healthcare providers to promote diagnostic tests.
Digital Outreach
Digital marketing efforts utilize social media, SEM, and email to inform and guide both healthcare professionals and patients toward testing services.
Content Marketing
Educational resources and patient-authored blogs are used to build awareness and support the physician-ordered testing model.
Partnership Expansion
Collaborations in February 2025 with PATHOMIQ and in Q4 2024 with jscreen expand the company's reach and service offerings.
Direct-to-Consumer Growth
The November 2022 acquisition of Gateway Genomics broadened direct-to-consumer access, particularly for prenatal testing.
Service Efficiency
Maintaining high customer satisfaction through efficient operations, with 88% of samples processed within industry-leading turnaround times.
Myriad Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Myriad Company?
- What is Competitive Landscape of Myriad Company?
- What is Growth Strategy and Future Prospects of Myriad Company?
- How Does Myriad Company Work?
- What is Sales and Marketing Strategy of Myriad Company?
- What are Mission Vision & Core Values of Myriad Company?
- Who Owns Myriad Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.